Picking the winners: Outcome prediction in pleural disease
The burden imposed on patients and healthcare providers by pleural disease is ever growing; the available data suggest that globally around 1 in every 300 people is affected on an annual basis, with the reported incidence of a number of common pleural conditions seen to be increasing [ref]. This ris...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2018
|
| Summary: | The burden imposed on patients and healthcare providers by pleural disease is ever growing; the available data suggest that globally around 1 in every 300 people is affected on an annual basis, with the reported incidence of a number of common pleural conditions seen to be increasing [ref]. This rising caseload is particularly evident in the context of malignant pleural effusion (MPE), with an estimated 175,000 new cases every year in the United States alone; and an expectation that patient numbers will continue to grow given the increasing prevalence of cancer in an ageing population [ref]. Furthermore, the range of diagnostic and therapeutic interventions available to patients with pleural disease and their physicians [ref] means that identifying those individuals most likely to benefit from a particular treatment is becoming ever more important in an era of personalised medicine. |
|---|